Last updated: 2026-09-11 21:23:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
GT Biopharma Inc. (GTBP) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $8,65, with a market capitalization of $10,79M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $4,91 to $34,25. This page covers its latest market performance, valuation, price trends and company information.
$10,79M | |
$6,59 | |
$14 799,83 | |
$4,91 | |
$6,18 | |
522,76K | |
36,81K | |
-- | |
$34,25 | |
$4,91 | |
2,05% | |
-- |
GT Biopharma Inc. (GTBP) is trading at $8,58 in after-hours trading as of 2026-09-11 21:21:00, up 38,75% ($2,39) from the regular-session close of $6,18.
After-hours trading shows how investors are pricing GTBP after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, GT Biopharma Inc. (GTBP) moved from $7,22 to $8,65, representing a gain of 19,72% ($1,42).
The stock traded between $4,91 and $8,73 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 68,77 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 12,7%
GTBP is currently trading at $8,65, placing it 12,7% of the way from its 52-week low of $4,91 to its 52-week high of $34,25. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 1 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of GT Biopharma Inc. (GTBP) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.